Pricing Log in Create free account
Friday 6 November 2026 Export KMDA’s income statement to Excel — free account

Kamada Ltd.

KMDA Healthcare Drug Manufacturers Specialty & Generic

Kamada Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $180.5 million, up 12.1% from fiscal 2024.

Revenue
+22.7%
EPS
+23.1%
Free cash flow
+165.7%
Total debt
−38.8%

Quarter to June 2026, against a year earlier

7.22 0.35 +5.09%
Market cap
$396.3M
P/E
19.0×
Fwd P/E
0.0×
Dividend yield
5.82%
F-score
7/9
Altman Z
3.33
Beneish M
−2.35
Dividend safety
50/100
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 1.65
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — 2 — —
Insider Ownership 45.31%

Capital & Financial Ratios $m

Size
Market Cap 396.33
Revenue ttm 191.85
Net income ttm 22.25
Free cash flow ttm 26.32
Net debt Q (64.10)
Valuation
P/E 19.00
Forward P/E 0.00
Price / sales 2.18
Forward P/S Powerpack
Price / FCF 15.88
Price / book 1.55
Financial health
Current ratio Q 4.06 (at or above 1.5: strong)
Debt / equity Q 0.02 (at or below 0.5: strong)
Interest coverage Q 25.63
Growth
Revenue growth Q +22.72% (above 0%: growing)
Operating income growth Q +34.49% (above 0%: growing)
EPS, this year +30.95% (at or above 15%: strong)
EPS, next year A +20.77% (at or above 15%: strong)
Revenue, next year A +8.07%
EPS, past 5 yrs −1.63% (below 0%: weak)
EPS, next 5 yrs A +21.04% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.9×, against a ten-year median of 1.7×; over the ten years it ranged from 0.8× in 2017 to 3.1× in 2017.
P/E against its own 10 years 43.73%
10-year low 10-year high
P/S against its own 10 years 58.32%
10-year low 10-year high
P/B against its own 10 years 43.00%
10-year low 10-year high
EV/Sales against its own 10 years 62.65%
10-year low 10-year high
EV/FCF against its own 10 years 39.26%
10-year low 10-year high

Dividends

Yield
5.82%
Annual rate
0.42
Payout ratio
110.5%
  1. 0.42 ’26
paid change on the year, %

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 56 78 75 70
Receivables 26 27 33 43
Inventory 88 79 85 87
Other — — — —
170 184 193 200
2023 2024 2025 Q'26
Payables 33 37 35 41
ST’ Debt 15 10 10 6
Other — — — —
50 49 47 49

Compound Annual Growth %

10y 5y 3y
Sales 9.95% 6.25% 11.74%
Cash Flow 0.00% 5.94% (3.75%)
Earnings 0.00% 3.34% 0.00%
Book Value 14.01% 8.54% 15.20%

Earnings Trends EPS, adjusted, against the consensus

Jun 2026 Estimate 0.12 Actual 0.16

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Sep 2025 0.10 0.09 Miss by 0.01
Dec 2025 0.09 0.06 Miss by 0.03
Mar 2026 0.12 0.07 Miss by 0.05
Jun 2026 0.12 0.16 Beat by 0.04
Sep 2026 0.13 — Reports 9 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.07 0.16 — — —
’25 0.07 0.13 0.09 0.06 0.35
’24 0.04 0.08 0.07 0.07 0.25
’23 (0.04) 0.04 0.06 0.09 0.15
’22 (0.04) (0.09) 0.01 0.07 (0.05)
’21 0.06 0.02 (0.02) (0.11) (0.05)
’20 0.12 0.08 0.15 0.04 0.38
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 45 55 — — —
’25 44 45 47 45 180
’24 38 42 42 39 161
’23 31 37 38 36 143
’22 28 24 32 45 129
’21 25 24 23 31 104
’20 33 33 35 32 133
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 0 18 — — —
’25 (1) 8 10 8 25
’24 1 14 22 10 48
’23 (3) 2 1 4 4
’22 5 11 5 7 29
’21 2 (3) (3) (5) (9)
’20 (2) 11 (2) 13 19
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) 16 — — —
’25 (2) 6 7 5 16
’24 (2) 11 20 7 37
’23 (4) 1 (1) 2 (2)
’22 5 10 4 6 25
’21 2 (5) (4) (6) (13)
’20 (3) 10 (4) 11 14
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 77 103 114 127 133 104 129 143 161 180 192 +9.8% 195 220 239 +9.8%
Gross margin, % 27.56 31.21 36.23 39.11 35.69 29.26 36.11 38.94 43.47 42.34 40.82 +14.8 pt
EBT (5) 7 20 23 19 (2) (2) 8 13 23 27 n/m
EBT margin, % (6.47) 6.97 17.77 18.07 13.93 (1.82) (1.75) 5.91 8.28 13.00 13.91 +19.5 pt
Net income (7) 7 22 22 17 (2) (2) 8 14 20 22 n/m
Per share, $
Per share, $ Revenue 2.13 2.71 2.84 3.15 3.02 2.31 2.89 2.92 2.80 3.13 3.31 +4.4%
Earnings (0.18) 0.18 0.55 0.55 0.39 (0.05) (0.05) 0.17 0.25 0.35 0.38 n/m
Cash flow 0.05 0.10 0.26 0.68 0.43 (0.20) 0.64 0.09 0.83 0.44 0.62 +26.8%
Capex (0.07) (0.11) (0.07) (0.06) (0.12) (0.08) (0.08) (0.12) (0.19) (0.17) (0.16) +10.2%
Free cash flow (0.02) (0.01) 0.19 0.63 0.31 (0.28) 0.55 (0.03) 0.64 0.27 0.45 n/m
Book value 1.83 2.36 2.79 3.36 4.05 3.95 3.93 5.00 4.51 4.67 4.66 +10.9%
Shares, m 36 38 40 40 44 45 45 49 57 58 58 +5.2%
Valuation, ×
Valuation, × P/E 0.00 28.24 9.09 12.65 16.62 0.00 0.00 38.50 23.42 20.17 19.00 14.9
P/S 2.75 1.77 1.76 2.17 2.15 2.84 1.44 2.11 2.18 2.26 2.18 2.1
P/B 3.19 2.04 1.79 2.04 1.60 1.67 1.06 1.23 1.35 1.51 1.55 1.7
EV/Sales 2.40 1.37 1.33 1.59 1.33 3.03 1.54 1.90 1.82 1.95 1.90 1.8
EV/FCF (265.24) (283.02) 19.75 8.00 12.99 (25.02) 8.02 (177.28) 7.94 22.50 13.85 (67.1)
Cash, $m
Cash, $m Operating cash flow 2 4 11 28 19 (9) 29 4 48 25 36 +33.5%
Capex (3) (4) (3) (2) (5) (4) (4) (6) (11) (10) (9) +15.9%
Free cash flow (1) 0 8 25 14 (13) 25 (2) 37 16 26 n/m
Balance, $m
Balance, $m Working capital 50 67 87 111 153 76 63 120 135 146 150 +12.6%
Net debt (27) (41) (49) (73) (109) 19 13 (41) (68) (66) (64) +10.4%
Shareholders’ equity 67 89 112 135 179 177 176 244 259 269 270 +16.8%
Returns, %
Returns, % ROA (6.68) 6.22 17.14 14.27 8.92 (0.84) (0.72) 2.45 3.98 5.38 5.92 +12.1 pt
ROIC (8.59) 9.60 19.13 22.91 17.26 (0.22) 1.50 3.09 6.55 8.06 8.47 +16.7 pt
ROE (9.67) 8.83 22.09 17.97 10.92 (1.25) (1.32) 3.94 5.74 7.64 8.40 +17.3 pt
People
People Employees 377 413 408 429 408 357 380 378 420 462 — +2.3%
Revenue/emp, $m 0.21 0.25 0.28 0.30 0.33 0.29 0.34 0.38 0.38 0.39 — +7.4%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Kamada Ltd. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
EVO Evotec AG $630.4M — (loss-making) — (loss-making) −12.98% (below 0%: shrinking) n/m −9,727.20% (below 0%: shrinking) (1.00%) (77.50%) Compare
TKNO Alpha Teknova, Inc. $486.2M — (loss-making) — (loss-making) +21.52% (above 0%: growing) n/m +40.94% (above 0%: growing) 37.99% (25.24%) Compare
AQST Aquestive Therapeutics, Inc. $460.0M — (loss-making) — (loss-making) −40.99% (below 0%: shrinking) n/m +40.78% (above 0%: growing) 52.28% (191.46%) Compare
EOLS Evolus, Inc. $448.8M — (loss-making) — (loss-making) +13.03% (above 0%: growing) n/m +77.73% (above 0%: growing) 65.02% (10.81%) Compare
TLRY Tilray Brands, Inc. $415.3M — (loss-making) — (loss-making) +22.74% (above 0%: growing) n/m −159.66% (below 0%: shrinking) 30.14% (9.35%) Compare
KMDA Kamada Ltd. $396.3M 18.1× — (loss-making) +22.72% (above 0%: growing) +23.08% (above 0%: growing) +165.71% (above 0%: growing) 40.91% 17.32%
ACB Aurora Cannabis Inc. $341.2M — (loss-making) — (loss-making) −31.15% (below 0%: shrinking) n/m −293.56% (below 0%: shrinking) 52.73% (12.92%) Compare
EBS Emergent Biosolutions Inc. $300.8M — (loss-making) — (loss-making) −52.40% (below 0%: shrinking) n/m +1,892.98% (above 0%: growing) 26.55% (33.91%) Compare
CGC Canopy Growth Corporation $283.5M — (loss-making) — (loss-making) +12.41% (above 0%: growing) n/m −117.60% (below 0%: shrinking) 27.40% (27.24%) Compare
Median of peers $432.1M — — −0.28% — −38.41% 34.07% (26.24%)

All 84 Drug Manufacturers Specialty & Generic stocks →

Kamada Ltd. (KMDA) Latest News

6 Oct

Impact 4 · · GlobeNewswire

27 Sep

Impact 4 · · MarketBeat

17 Sep

Impact 4 ·

19 Aug

Impact 3 · · The Motley Fool transcript

17 Aug

Impact 3 ·

12 Aug

Impact 4 ·
Impact 4 ·
Impact 3 · · Moby transcript
Impact 3 · · MarketBeat transcript
Impact 3 ·
Impact 3 ·

20 Jul

Impact 4 ·

13 Jul

Impact 3 ·

1 Jun

Impact 3 · · GlobeNewswire

13 May

Impact 4 · · GuruFocus.com
Impact 4 · · The Motley Fool transcript
Impact 4 · · MarketBeat
Impact 4 · · Zacks
Impact 4 · · Benzinga transcript
Impact 4 · · GlobeNewswire
Impact 3 · · Moby
Impact 3 · · Zacks

8 May

Impact 3 · · Zacks

26 Mar

Impact 4 · · GlobeNewswire

11 Mar

Impact 4 · · GuruFocus.com
Impact 4 · · Zacks
Impact 4 · · Associated Press Finance
Impact 4 · · GlobeNewswire
Impact 3 · · MarketBeat
Impact 3 ·
stockrow.com/KMDA · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com